Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exelixis Slashes Staff Again, Focuses All Internal Development on XL184

This article was originally published in The Pink Sheet Daily

Executive Summary

As many as 65% of the oncology biotech's employees could be shown the door as the company ceases research on all but one drug candidate.
Advertisement

Related Content

Panel: Oncology Business Models Determined By Capital And Culture
Solution Development: A Model For Structuring Biotechs And Developing Better Drugs
Oncology Start-up Cyterix Pharmaceuticals Launches With $9.2MM From VCs
Oncology Start-up Cyterix Pharmaceuticals Launches With $9.2MM From VCs
Blueprint Medicines Takes $40MM From Third Rock To Build Oncology Platform
Celldex To Fly Solo With Phase III Trial Of Brain Cancer Vaccine
Exelixis Puts '184 Back in Spotlight With "Dramatic" Prostate Cancer Results
FDA Approves Amgen's Denosumab For First Oncology Indication
Biogen Makes Counterintuitive Move To Tap Exelixis’s George Scangos As CEO
Biogen Makes Counterintuitive Move To Tap Exelixis’s George Scangos As CEO

Topics

Advertisement
UsernamePublicRestriction

Register

PS071555

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel